TrialSignal
Clinical trial intelligence report
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05598593-Jul 28, 2026
NCT ID
NCT05598593
Status
UNKNOWN
Phase
PHASE2
Sponsor
First Affiliated Hospital of Zhejiang University
Executive brief
Investment-Ready Snapshot
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study is a PHASE2 clinical asset sponsored by First Affiliated Hospital of Zhejiang University in Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. SEO and diligence focus: cytarabine+thiotepa+ fludarabine + busulfan, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05598593
Indication
Cytarabine+Thiotepa + Fludarabine + Busulfan
Modality
small molecule
Target
cytarabine+thiotepa+ fludarabine + busulfan
Intervention
cytarabine+thiotepa+ fludarabine + busulfan
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.